Fact CheckerSign in

NCT06578507RecruitingPhase 2

Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease

Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease: a Single-group, Non-randomised, Open-label Study (KID-BID)

Source: ClinicalTrials.gov · Last updated 1 Oct 2026

Brief summary (registry, in English)

The purpose of this interventional, phase II, national, multicentric, non-randomised, open-label study is to evaluate the pharmacokinetics (PK), efficacy and safety of Hydroxycarbamide Paediatric dispersible tablets with a twice daily dosing regimen in children with Sickle Celle Disease between 9 months to 11 years of age. Participants will: * Take Hydroxycarbamide twice a day every day for 12 months * Visit the clinic at screening, baseline, 1, 3, 6, 9 and 12 months

Status (registry)
Recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
50 (estimated)
First submitted
22 Aug 2024
Start date
21 Jan 2025
Primary completion date
Feb 2028
Lead sponsor
Theravia
NCT number
NCT06578507

What you commit to

  • Study type: Interventional · Phase 2
  • Planned participants: 50
  • From 21 Jan 2025 to the primary completion date, Feb 2028
  • 7 sites in 2 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients treated with other SCD-modifying therapies,

Other illness

  • Patient with a stage 3, 4 or 5 chronic kidney disease,
  • Patients known to be infected with human immunodeficiency virus, hepatitis B virus, or hepatitis C virus,
  • Known hypersensitivity or allergy to the excipients,
  • Any surgical or medical condition or any significant illness that, in the opinion of the investigator, constitutes a risk or a contraindication to the participation of the patient to the study, or that may interfere with the objectives, conduct or evaluation of the study,
  • Any documented history of a clinical stroke or intracranial haemorrhage, or an uninvestigated neurologic finding within the past 12 months.

Other

  • Participation in any other clinical study for any other pharmaceutical product within 4 weeks preceding the inclusion visit,
  • Patients who have had chronic blood transfusion or transfusion in the last 3 months preceding the inclusion visit,
  • Female patients who are pregnant or lactating,

Who the study is looking for

  • Written informed consent, signed and dated by both parents or by the legally acceptable representative(s) of the children, and, if possible, assent from the children,
  • HbSS or HbSβ0 SCD,
  • Aged between 9 months and 11 years old,
  • Hydroxycarbamide naïve,
  • Parent(s) or legally acceptable representative(s) capable of communicating with the investigator and understanding the requirements and constraints of the study protocol and willing to comply with the study requirements,
  • Contraception criterion, if applicable: for patients who are sexually active
  • Affiliated to a social security plan or beneficiary of a similar insurance plan,
  • Patient must meet the following laboratory values : Absolute Neutrophil Count ≥ 1.0x109/L, Platelets ≥ 75x109/L and Haemoglobin (Hgb) \> 5.5 g/dL,
  • Transcranial Doppler (TCD) in the last 12 months indicating low risk for stroke is required for children over 18 months of age.

Age in the registry: 9 months to 11 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (7)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Centre Hospitalier Intercommunal Créteil
Coordinator of this site? Confirm its status
CréteilFranceRecruiting
GHEF, Site de Marne-la-Vallée
Coordinator of this site? Confirm its status
JossignyFranceRecruiting
Hopital Bicetre
Coordinator of this site? Confirm its status
Le Kremlin-BicêtreFranceRecruiting
Institut d'hématologie et d'oncologie Pédiatrique iHOPE
Coordinator of this site? Confirm its status
LyonFranceSuspended
Hopital Necker Enfants Malades
Coordinator of this site? Confirm its status
ParisFranceRecruiting
CH Saint Denis
Coordinator of this site? Confirm its status
Saint-DenisFranceRecruiting
Centre Hospitalier de Cayenne
Coordinator of this site? Confirm its status
CayenneFrench GuianaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.